Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.
By R. Motzer, J. Bacik, B. Murphy, P. Russo, M. Mazumdar. Journal of Clinical Oncology, 2002
1,529 citations recorded by the source corpus.
Subfields: Cancer Research, Molecular Biology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/c6829c0087a62707c705e50e38f98e6f8f098414
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. (2009, methodology): “Karnofsky performance status, anemia, hypercalcemia, and a short time from diagnosis to treatment are factors that have been previously reported in the MSKCC criteria and may reflect increased tumor burden, aggressive tumor biology, and/or paraneoplastic processes.(13,14,19,20) Neutrophilia(21) and ”
- Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. (2005, methodology): “Treatment arms were evenly balanced for the stratification criteria and were reasonably well balanced for prior therapy, sex, age, and the Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic criteria.(16) Forty-five percent of all patients had liver or bone metastases, 31% had their primary tu”
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma (2009, methodology): “Per historical data, overall survival of patients treated with IFN- as first-line therapy had been approximately 13 months.(7) A total of 390 events were required for a two-sided, unstratified log-rank test with an overall two-sided significance level of P 0.”
- Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. (2004, background): “The median survivals of the heavily pretreated patients in the different risk groups in this study were compared with the median survivals of first-line RCC patients in the different risk groups treated with IFN- [40].”
- Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. (2004, methodology): “Similar clinical features were examined for prognostic importance by univariate and multivariate analyses and compared with those previously reported in patients receiving first-line therapy [13].”
- Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells (2011, background): “Although early clinical trials of systemic administration of type I IFNs showed encouraging results for the treatment of a broad range of tumors (Neidhart et al., 1984; Motzer et al., 2002), the mechanism by which exogenously administered type I IFNs induces antitumor activity has remained elusive.”
- EAU guidelines on renal cell carcinoma: 2014 update. (2010, neutral): “Renal function should be estimated when there is a solitary kidney or bilateral tumours; when renal function is compromised, as indicated by increased serum creatinine; or when there is risk of future renal impairment from comorbid disorders affecting renal function [10].”
- Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. (2010, methodology): “Twenty-six percent, 64%, and 10% of patients had goodrisk, intermediate-risk, and poor-risk disease, respectively.(3)”